|
CDSCO mandates inclusion of AGEP as ADR in PILs of phenytoin formulations
|
|
Gireesh Babu, New Delhi
November 20 , 2026
|
|
|
The Central Drugs Standard Control Organisation (CDSCO) has asked all State Licensing Authorities (SLAs) to direct the manufacturers of anticonvulsant drug phenytoin formulations that the Prescribing Information Leaflet (PIL) of these formulations should mention Acute Generalised Exanthematous Pustulosis (AGE?) as an Adverse Drug Reaction (ADR) of the drug.
The decision follows recommendation by the National Coordination Centre for Pharmacovigilance Programme of India (NCC-PvPI), under the Indian Pharmacopoeia Commission (IPC), and an expert committee which advises the drugs regulator.
Acute Generalised Exanthematous Pustulosis (AGE?) is a rare skin reaction caused by a medication, in the form of small, non-infectious pus-filled bumps on red, swollen skin.
Phenytoin formulations, which come in different forms, are used to control certain seizures, and to prevent seizures associated with surgery to the brain or nervous system. The drug works by bringing down abnormal electrical activity in the brain.
The central drugs regulator said that a safety signal of AGE? associated with Phenytoin was identified after evaluation of Periodic Safety Update Report (PSUR) data of these formulations by the CDSCO.
The signal was examined in conjunction with the Individual Case Safety Reports (ICSRs) of Phenytoin formulations available in the Pharmacovigilance Programme of India (PvPI) database which was discussed in the 9th Signal Review Panel (SRP) of the Pharmacovigilance Programme of India (NCC-PvPI), held on November 29, 2016.
Based on the combined findings of the CDSCO PSUR data evaluation and the PvPI ICSR assessment, the SRP made a recommendation to CDSCO to take necessary measures to incorporate AGEP as an ADR in to the PIL of the Phenytoin based medical products marketed in the country.
The recommendations of NCC-PvPI was subsequently reviewed by the Subject Expert Committee (SEC) on Neurology & Psychiatry during its meeting held on March 17, 2017 at CDSCO headquarters in New Delhi.
After detailed deliberations, the committee recommended that CDSCO should request the State Drugs Controllers to direct the manufacturers to incorporate the ADR in the corresponding PIL of the drug."
In a communication to all State and Union Territory licensing authorities on November 10, 2026, the Post Marketing Drugs Safety Monitoring Division of the CDSCO, said, "The recommendation of the SEC has been considered by this office. Accordingly, you are requested to direct the manufacturers of Phenytoin formulations under your jurisdiction to mention "Acute Generalised Exanthematous Pustulosis (AGEP)" as an adverse drug reaction in the Package insert/Promotional Literature of the drug".
The NCC-PvPI produces the signal, which is preliminary in nature, based on the information on a possible causal relationship between an adverse event and a drug. Referring to the World Health Organisation's (WHO) definition, it adds that usually more than one report is required to generate a signal, depending on the seriousness of the event and the quality of the information.
According to the IPC, the signal is produced by the NCC-PvPI and presents information derived from the NCC-PvPI national ICSR database management system, that is, VigiFlow. This database contains a summary of case reports of suspected adverse drug reactions, submitted by Adverse drug reaction Monitoring Centres (AMCs) across India.
PvPI Signal Review Panel assesses the database for the occurrence of signals of possible importance for public health, drug regulation, and science. The dissemination of identified signals by the PvPI is restricted to AMCs, regulatory authority staff, and their advisers participating in the pharmacovigilance programme of the country and the NCC has no responsibility for contacting all marketing authorisation holders.
The CDSCO and the IPC are responsible for deciding further action including communicating the information in Signal to relevant health professionals, and to the responsible market authorisation holders, within their jurisdictions.
|
|

|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|